Related Experiment Video
Updated: May 18, 2026
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
Melanoma brain metastases and vemurafenib: need for further investigation
Nicole M Rochet1, Roxana S Dronca, Lisa A Kottschade
1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. With the development of targeted agents for the treatment of metastatic melanoma, a great deal of interest has focused on whether selective BRAF inhibitors may play a role in the treatment of brain metastases in lieu of or in addition to surgery and/or radiation therapy. However, relatively little is known about the intracranial effectiveness of vemurafenib, the only US Food and Drug Administration-approved selective BRAF V600E inhibitor, because patients with brain metastases have historically been excluded from vemurafenib clinical trials. We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom treatment with vemurafenib resulted in prompt extracranial disease response but progression of metastatic disease in the brain. Further, we discuss possible mechanisms responsible for the suboptimal central nervous system response observed in these patients and alternative therapies for patients with melanoma metastatic to the brain.
Insights
Vemurafenib effectively treats advanced melanoma but shows limited efficacy against brain metastases in BRAF V600E patients. Further research is needed for optimal central nervous system treatment strategies.
Area of Science:
- Oncology
- Neuro-oncology
- Dermatology
Background:
- Advanced melanoma frequently metastasizes to the brain, significantly increasing morbidity and mortality.
- Targeted therapies, such as BRAF inhibitors, offer new treatment avenues for metastatic melanoma.
- Intracranial efficacy of vemurafenib, a BRAF V600E inhibitor, remains poorly understood due to trial exclusions.
Observation:
- Three patients with BRAF V600E mutated metastatic melanoma were treated with vemurafenib.
- All patients experienced significant extracranial tumor response.
- Despite extracranial response, all patients exhibited progression of brain metastases.
Findings:
- Vemurafenib demonstrated prompt extracranial disease control in metastatic melanoma.
- Suboptimal central nervous system (CNS) response was observed in patients with brain metastases.
- The study highlights potential limitations of vemurafenib in treating melanoma brain metastases.
Implications:
- Current BRAF inhibitors may not be sufficient for managing melanoma brain metastases.
- Further investigation into mechanisms of limited CNS penetration or resistance is warranted.
- Alternative or combination therapies are crucial for improving outcomes in patients with melanoma metastatic to the brain.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:56Treatment Resistant Cancers